No. INGRS066 30 March 2021 Subject : Management Discussion & Analysis (MD&A) for the consolidated financial statements for the financial year ended 31 January 2021 To : The President The Stock

subsidiaries report the operating results for the first quarter of year 2019 of the Company and its subsidiaries in the consolidated financial statements for the three-month period ended 31 March 2019 which have

subsidiaries (“KSL”) would like to report our financial performance of the 2nd quarter year 2019 (Feb 2019 - Apr 2019). The Company recorded total revenue of THB 3,334 million compare to THB 3,586 million last

/2020 dated February 22, 2020 approved the Company’s Financial Statement ending December 31, 2019. The Company would like to clarify the year ended December 31, 2019 earnings results, as follows

appreciation to competitors, especially from Vietnam. - QSR business recorded its revenue of Baht 143.0 Million that 3.1% increased from 2018 or by Baht 4.2 Million, resulted from distribution channel

amount not exceeding 200 MB; totaling to not exceeding 250 MB. In order to expand investment in business concerning healthcare, esthetic, and cosmetic distribution related to core business of the Company

trademark “Wuttisak Clinic” at the amount not exceeding 200 MB; totaling to not exceeding 250 MB. In order to expand investment in business concerning healthcare, esthetic, and cosmetic distribution related

100.00 350.29 100.00 52.45 14.97 Cost of services 390.38 96.93 362.13 103.38 28.25 7.80 Distribution cost 22.31 5.54 23.05 6.58 -0.74 -3.20 Administrative expenses 44.71 11.10 43.59 12.44 1.12 2.57

100.00 90.56 100.00 15.72 17.36 Cost of services 99.60 93.71 92.72 102.39 6.88 7.42 Distribution cost 6.56 6.17 3.06 3.38 3.50 114.38 Administrative expenses 13.27 12.49 10.43 11.52 2.84 27.23 Financial

/2019 dated November 7, 2019 approved the Company’s Interim Financial Information ending September 30, 2019. The Company would like to clarify the nine-month period ended September 30, 2019 earnings